Market Place
Sourcing Support
After Rubius collapse and brief stop at startup, Pablo Cagnoni start at Incyte
08 May 2023 //
ENDPTS
After last-ditch effort, Rubius moves to dissolve
22 Feb 2023 //
FIERCE BIOTECH
Ex-Rubius CEO dusts himself off at a different Flagship biotech
18 Nov 2022 //
ENDPTS
Former Rubius CEO to lead buzzy Flagship startup
17 Nov 2022 //
BIOPHARMADIVE
Rubius Announces Process to Explore Strategic Alternatives & Leadership Changes
02 Nov 2022 //
GLOBENEWSWIRE
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
19 Sep 2022 //
GLOBENEWSWIRE
Rubius resorts to layoffs & abandons its lead programs as its survival strategy
13 Sep 2022 //
ENPTS
Rubius Therapeutics Announces Strategic Update
13 Sep 2022 //
GLOBENEWSWIRE
Rubius Therapeutics to Provide Strategic Update
12 Sep 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
26 Jul 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors
14 Jul 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Presents Updated Data from its T1D Preclinical Program
22 Jun 2022 //
GLOBENEWSWIRE
Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
Rubius Tx to Present Trials in Progress Poster for the PI/II Trial of RTX-224
26 May 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
24 May 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Reports First Quarter 2022 Financial Results
10 May 2022 //
GLOBENEWSWIRE
Rubius Therapeutics to Announce First Quarter 2022 Financial Results
26 Apr 2022 //
GLOBENEWSWIRE
Rubius touts new data for lead program, but shares routed as investors flee
09 Apr 2022 //
ENDPTS
Rubius Tx to Host Investor Webcast to Discuss Updated Clinical Data at AACR
07 Apr 2022 //
GLOBENEWSWIRE
Rubius Tx to Present Results from Single-Agent P1Trial of RTX-240 at AACR
08 Mar 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Reports Q4 and Full Year 2021 Financial Results
25 Feb 2022 //
GLOBENEWSWIRE
Rubius Begins Dosing of First Patient in Phase 1/2 Trial of RTX-224
13 Jan 2022 //
GLOBENEWSWIRE
Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives
10 Jan 2022 //
GLOBENEWSWIRE
Rubius to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference
04 Jan 2022 //
GLOBENEWSWIRE
Rubius Therapeutics to Highlight the Power ofRED PLATFORM®
16 Dec 2021 //
GLOBENEWSWIRE
Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts
02 Dec 2021 //
GLOBENEWSWIRE
Rubius Therapeutics to Participate in Evercore ISI 4th Annual
23 Nov 2021 //
GLOBENEWSWIRE
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
09 Nov 2021 //
GLOBENEWSWIRE
Rubius Therapeutics Announces Preclinical Data for RTX-224
01 Oct 2021 //
GLOBENEWSWIRE
Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer
30 Aug 2021 //
GLOBENEWSWIRE
Flagship woos another Big Pharma BD exec to biotech. RBC therapies anyone?
30 Aug 2021 //
ENDPTS
Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer
29 Jul 2021 //
GLOBENEWSWIRE
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
22 Jul 2021 //
GLOBENEWSWIRE
Rubius Therapeutics to Announce Second Quarter 2021 Financial Results
22 Jul 2021 //
GLOBENEWSWIRE
Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data
15 Jul 2021 //
GLOBE NEWSWIRE
Rubius Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA
23 Jun 2021 //
GLOBENEWSWIRE
Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 RTX-321
18 May 2021 //
PRESS RELEASE
Rubius Announces Publication of RTX-321 Preclinical Data in Nature
12 May 2021 //
GLOBENEWSWIRE
Rubius Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321
13 Apr 2021 //
GLOBNEWSWIRE
Rubius Presents Initial Clinical Results from Ongoing Pha1/2 Trial of RTX-240
09 Apr 2021 //
GLOBENEWSWIRE
Rubius reports positive data from Phase I/II cancer trial of RBC therapy
17 Mar 2021 //
CLINICALTRIALSARENA
Rubius Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240
15 Mar 2021 //
GLOBENEWSWIRE
Rubius chief lays out the first human data on their lead red cell drug
15 Mar 2021 //
ENDPTS
Rubius to Present Initial Results from the Ongoing Ph 1/2 Trial of RTX-240
10 Mar 2021 //
GLOBENEWSWIRE
Rubius Therapeutics Provides Operational Update and Outlines 2021
11 Jan 2021 //
GLOBENEWSWIRE
Rubius Presents Preclinical Data for Red Cell Oncology, RTX-240
09 Nov 2020 //
PRESS RELEASE
Rubius Announces Dosing of First Patient with Relapsed/Refractory
05 Nov 2020 //
GLOBENEWSWIRE
Rubius Presents Preclinical Data for RTX-321, a Red Cell Therapeutic™
28 Oct 2020 //
GLOBENEWSWIRE
Rubius Announces Preclinical Data Supporting its Lead Clinical Oncology, RTX-240
15 Oct 2020 //
GLOBENEWSWIRE
Rubius Provides Update on Clinical Trial Progress for Lead Oncology RTX-240
30 Jun 2020 //
GLOBENEWSWIRE
Rubius marks milestone in PhI/II as CFO departs; Owkin closes $70M Series A;
30 Jun 2020 //
ENDPTS
Rubius Therapeutics Announces Dosing of First Patient in Ph1/2 Trial of RTX-240
07 May 2020 //
GLOBENEWSWIRE
Rubius Announces Preclinical Data from Red Cell Therapeutic Oncology Programs
29 Apr 2020 //
GLOBENEWSWIRE
Rubius scraps lead candidate as it exits rare disease drugmaking
12 Mar 2020 //
BIOPHARMADIVE
Rubius scraps lead drug after seeing `uninterpretable` data
12 Mar 2020 //
FIERCE BIOTECH
Rubius Announces First Patient Dosed in Phase 1b Trial of RTX-134
30 Jan 2020 //
GLOBENEWSWIRE
It’s only test tubes and mice, but Rubius hails first new data cancer drugs
02 Apr 2019 //
STATNEWS
Boom: 2018’s biotech IPOs
02 Jan 2019 //
NATURE
